[go: up one dir, main page]

HRP20140316T1 - Humana antitijela protiv virusa hepatitisa c (hcv) i njihova uporaba - Google Patents

Humana antitijela protiv virusa hepatitisa c (hcv) i njihova uporaba Download PDF

Info

Publication number
HRP20140316T1
HRP20140316T1 HRP20140316AT HRP20140316T HRP20140316T1 HR P20140316 T1 HRP20140316 T1 HR P20140316T1 HR P20140316A T HRP20140316A T HR P20140316AT HR P20140316 T HRP20140316 T HR P20140316T HR P20140316 T1 HRP20140316 T1 HR P20140316T1
Authority
HR
Croatia
Prior art keywords
antibody
antigen
seq
hcv
binding part
Prior art date
Application number
HRP20140316AT
Other languages
English (en)
Inventor
Theresa Broering
Susan Sloan
Gregory J. Babcock
Donna Ambrosino
William D. Thomas
Original Assignee
University Of Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Massachusetts filed Critical University Of Massachusetts
Publication of HRP20140316T1 publication Critical patent/HRP20140316T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Izolirano humano monoklonsko antitijelo, ili njegov dio koji veže antigen, naznačeno time da antitijelo, ili njegov dio koji veže antigen, sadrži: (a) varijabilne regije teškog i lakog lanca koje sadrže SEQ ID NOs:1 i 2; ili (b) varijabilnu regiju teškog lanca CDR3 sekvence koja sadrži SEQ ID NO:9, varijabilnu regiju lakog lanca CDR3 sekvence koja sadrži SEQ ID NO:18, varijabilnu regiju teškog lanca CDR2 sekvence koja sadrži SEQ ID NO:8, varijabilnu regiju lakog lanca CDR2 sekvence koja sadrži SEQ ID NO:17, varijabilnu regiju teškog lanca CDR1 sekvence koja sadrži SEQ ID NO:7 i varijabilnu regiju lakog lanca CDR1 sekvence koja sadrži SEQ ID NO:16.
2. Antitijelo prema zahtjevu 1, naznačeno time da antitijelo je antitijelo pune duljine.
3. Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 1 naznačeno time da: - sadrži Fc domenu; ili - je antitijelo jednostrukog-lanca; ili - je Fab fragment.
4. Izolirani polipeptid naznačen time da sadrži dio koji veže antigen za antitijelo prema bilo kojem prethodnom zahtjevu.
5. Pripravak naznačen time da sadrži antitijelo, ili dio koji veže antigen, prema bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljiv nosač.
6. Izolirana nukleinska kiselina naznačena time da kodira varijabilnu regiju antitijela koje veže HCV, te navedena nukleinska kiselina sadrži SEQ ID NO:25 i SEQ ID NO:26.
7. Ekspresijski vektor ili stanica domaćin naznačeni time da sadrže nukleinsku kiselinu prema zahtjevu 6.
8. Komplet naznačen time da sadrži jedno ili više izoliranih monoklonskih antitijela, ili njegov dio koji veže antigen kako je navedeno u bilo kojem zahtjevu od 1 do 3, te instrukcije za uporabu za liječenje HCV-posredovane bolesti.
9. Izolirano monoklonsko antitijelo, ili njegov dio koji veže antigen, prema bilo kojem zahtjevu od 1 do 3 naznačeno time da je za uporabu u postupku liječenja subjekta koji ima HCV infekciju.
10. Antitijelo, ili njegov dio koji veže antigen, prema bilo kojem zahtjevu od 1 do 3, za uporabu u postupku liječenja HCV infekcije prema zahtjevu 9 naznačeno time da: (a) subjekt je čovjek; ili (b) antitijelo, ili njegov dio koji veže antigen, je za intravensko, intramuskularno ili supkutano davanje.
11. Antitijelo, ili njegov dio koji veže antigen, prema bilo kojem zahtjevu od 1 do 3, za uporabu u postupku liječenja HCV infekcije prema zahtjevu 9, naznačeno time da postupak sadrži davanje navedenog antitijela, ili njegovog dijela koji veže antigen, u kombinaciji sa drugim terapeutskim sredstvom koje je odabrano od: (i) drugog antitijela, ili njegovog dijela koji veže antigen; (ii) antivirusnog sredstva; ili (iii) HCV cjepiva, koje je proizvoljno HCV2 E2 protein ili njegov fragment.
12. Pripravak za uporabu u postupku liječenja bolesti ili poremećaja posredovanog sa HCV kod sisavca, naznačen time da navedeni pripravak sadrži antitijelo, ili njegov dio koji veže antigen, prema bilo kojem zahtjevu od 1 do 3, u farmaceutski prihvatljivom nosaču.
13. Pripravak prema zahtjevu 12 za uporabu u postupku liječenja bolesti ili poremećaja posredovanog sa HCV prema zahtjevu 12, naznačen time da navedeni pripravak dodatno sadrži drugo antitijelo koje veže HCV.
14. Postupak otkrivanja HCV infekcije kod sisavca naznačen time da se sastoji od kontakta tjelesne tekućine dobivene iz sisavca s antitijelom prema bilo kojem zahtjevu od 1 do 3, ili njegovim dijelom koji veže antigen, te određivanja da li se javlja vezanje, a navedeno vezanje ukazuje na postojanje HCV infekcije.
HRP20140316AT 2007-02-21 2008-02-13 Humana antitijela protiv virusa hepatitisa c (hcv) i njihova uporaba HRP20140316T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90243207P 2007-02-21 2007-02-21
PCT/US2008/001922 WO2008108918A1 (en) 2007-02-21 2008-02-13 Human antibodies against hepatitis c virus (hcv) uses thereof

Publications (1)

Publication Number Publication Date
HRP20140316T1 true HRP20140316T1 (hr) 2014-05-09

Family

ID=39537518

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140316AT HRP20140316T1 (hr) 2007-02-21 2008-02-13 Humana antitijela protiv virusa hepatitisa c (hcv) i njihova uporaba

Country Status (21)

Country Link
US (2) US8551484B2 (hr)
EP (1) EP2125889B1 (hr)
JP (1) JP5642972B2 (hr)
KR (1) KR101518081B1 (hr)
CN (1) CN101679512A (hr)
AU (1) AU2008223561B2 (hr)
BR (1) BRPI0807929A2 (hr)
CA (1) CA2678888C (hr)
CY (1) CY1115282T1 (hr)
DK (1) DK2125889T3 (hr)
ES (1) ES2456961T3 (hr)
HR (1) HRP20140316T1 (hr)
IL (1) IL200432A (hr)
MX (1) MX2009008706A (hr)
NZ (1) NZ579706A (hr)
PL (1) PL2125889T3 (hr)
PT (1) PT2125889E (hr)
RS (1) RS53258B (hr)
SI (1) SI2125889T1 (hr)
WO (1) WO2008108918A1 (hr)
ZA (1) ZA200905762B (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143345A2 (en) * 2008-05-22 2009-11-26 University Of Massachusetts Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
CN101899419B (zh) 2009-05-25 2013-06-05 中国科学院上海生命科学研究院 昆虫杆状病毒表达系统及用其表达e2蛋白的方法
ES2978496T3 (es) 2009-07-08 2024-09-13 Kymab Ltd Modelos animales y moléculas terapéuticas
JP5813880B2 (ja) 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
CA3099156A1 (en) * 2011-10-24 2013-05-02 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
TW201546284A (zh) 2013-10-01 2015-12-16 Kymab Ltd 動物模式及治療分子
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
PL230663B1 (pl) * 2015-01-15 2018-11-30 Univ Gdanski Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
JP7464954B2 (ja) 2017-04-27 2024-04-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
CN109738648B (zh) * 2018-12-29 2021-09-17 山东莱博生物科技有限公司 稳定高效表达丙型肝炎病毒核心抗原抗体的工程细胞株及其应用
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN115362175A (zh) * 2020-02-11 2022-11-18 瑞泽恩制药公司 抗acvr1抗体及其用途
AU2022220616A1 (en) * 2021-02-12 2023-08-31 Merck Sharp & Dohme Llc Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5308750A (en) 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU663064B2 (en) 1990-10-12 1995-09-28 Abbott Laboratories Hepatitis C virus antibody
AU662517B2 (en) 1991-01-31 1995-09-07 Abbott Laboratories Monoclonal antibodies to putative HCV envelope region and methods for using same
FR2677372B1 (fr) 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
AU2501392A (en) 1991-08-21 1993-03-16 Abbott Laboratories Monoclonal antibodies to putative hcv ns5 proteins and methos for using same
ZA927837B (en) 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
JP2778886B2 (ja) 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
CN1189558C (zh) 1993-10-08 2005-02-16 诺沃奇梅兹有限公司 淀粉酶变体
EP1978033A3 (en) * 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
DE69739268D1 (de) 1996-11-08 2009-04-02 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
JP2001522599A (ja) 1997-11-06 2001-11-20 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断用及びワクチン用、ｃ型肝炎ウイルスエンベロープタンパク質由来マルチマーペプチド
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
EP1097172A1 (en) 1998-07-21 2001-05-09 Genmab A/S Anti hepatitis c virus antibody and uses thereof
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
JP2002528140A (ja) 1998-11-05 2002-09-03 ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体
US20030180284A1 (en) 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
IL137522A (en) 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
EP1355947A2 (en) * 2000-12-01 2003-10-29 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
DE60231475D1 (de) 2001-01-12 2009-04-23 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
ITRM20010336A1 (it) 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
JP4660189B2 (ja) 2002-07-03 2011-03-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット

Also Published As

Publication number Publication date
ZA200905762B (en) 2013-03-27
CA2678888A1 (en) 2008-09-12
KR20100014476A (ko) 2010-02-10
CY1115282T1 (el) 2017-01-04
IL200432A (en) 2015-02-26
WO2008108918A1 (en) 2008-09-12
EP2125889A1 (en) 2009-12-02
NZ579706A (en) 2012-03-30
PT2125889E (pt) 2014-04-15
PL2125889T3 (pl) 2014-06-30
JP5642972B2 (ja) 2014-12-17
ES2456961T3 (es) 2014-04-24
AU2008223561A1 (en) 2008-09-12
US8551484B2 (en) 2013-10-08
IL200432A0 (en) 2010-04-29
CN101679512A (zh) 2010-03-24
DK2125889T3 (da) 2014-04-14
US20140134175A1 (en) 2014-05-15
CA2678888C (en) 2015-04-14
AU2008223561B2 (en) 2013-10-03
BRPI0807929A2 (pt) 2014-06-24
US20120288510A1 (en) 2012-11-15
SI2125889T1 (sl) 2014-06-30
EP2125889B1 (en) 2014-01-15
KR101518081B1 (ko) 2015-05-06
HK1138297A1 (en) 2010-08-20
JP2010518854A (ja) 2010-06-03
RS53258B (en) 2014-08-29
MX2009008706A (es) 2009-09-14

Similar Documents

Publication Publication Date Title
HRP20140316T1 (hr) Humana antitijela protiv virusa hepatitisa c (hcv) i njihova uporaba
RU2462475C2 (ru) Антитела против вируса гепатита с
RU2425841C2 (ru) Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
JP2024038003A5 (hr)
JP2020522261A5 (hr)
HRP20191999T1 (hr) Monoklonska protutijela anti-faktora xi i postupci njihove uporabe
RU2019118359A (ru) Антитело к cd73 человека
JP2018512138A5 (hr)
JP2013506428A5 (hr)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2016123839A (ru) Новые модуляторы и способы их применения
JP2002521391A5 (hr)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
JP2010518854A5 (hr)
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
HRP20220918T1 (hr) Anti-transtiretinska antitijela
JP2018535650A5 (hr)
CN110028579B (zh) 一种抗尼帕病毒包膜糖蛋白的单克隆抗体及其应用
JP2015503909A5 (hr)
AU2003208000B2 (en) Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
JP2017523984A5 (hr)
FI3553084T3 (fi) Anti-adrenomedulliinivasta-aine (ADM) tai anti-ADM-vasta-ainefragmentti tai anti-ADM-non-Ig-skaffoldi elimen toimintahäiriön tai elimen vajaatoiminnan ehkäisemiseksi tai pienentämiseksi kroonisen tai akuutin taudin tai akuutin tilan omaavassa potilaassa
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78